Abstract: The present invention relates to an eco-friendly herbicide comprising 8 to 15% by weight of soft water, 1.5 to 5% by weight of canola oil, 0.2 to 1% by weight of potassium hydroxide, 78 to 88% by weight of pelargonic acid, 0.2 to 1% by weight of sodium alginate, 0.2 to 1% by weight of citric acid and 0.1 to 1% by weight of beet juice, and the herbicide provides the effects of being harmless to the human body and not causing soil contamination while exhibiting not only weed control but also bactericidal, insecticidal and harmful bird and animal repellent functions.
Abstract: L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates for treatment, amelioration and/or prevention of protein aggregation/tangles/plaques and diseases associated with protein aggregation/tangles/plaques. In particular, treatments and uses for L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates include Alzheimer's disease (AD), Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and Huntington disease (HD).
Type:
Grant
Filed:
July 12, 2021
Date of Patent:
May 7, 2024
Assignee:
THE INSTITUTE FOR ETHNOMEDICINE
Inventors:
Paul Alan Cox, Sandra Anne Banack, Deborah C. Mash
Abstract: In some aspects, the techniques described herein relate to a topical dermatologic acne treatment method using a cream. The treatment method uses two steps, first providing a bactericidal component and second providing a skin revitalizing complex. The bactericidal component clears the acne causing bacteria. The subsequent skin revitalizing complex revitalizes and conditions the skin and aids in return of natural skin flora and microbiome to prevent subsequent outbreaks. The skin revitalizing complex can include a variety of components such as: niacinamide, retinol, bakuchiol, green coffee bean extract, green tea extract, epilobium fleischeri extract, citric acid, dimethicone, and pentaerythrityl tetracaprylate. The skin revitalizing complex restores natural elasticity and oil production of the skin, decrease sebum production, and provide necessary conditioning of the skin to provide for the natural skin flora and microbiome to repopulate and flourish on a surface of the skin.
Abstract: Lipid-based delivery vehicles are provided. Nanoparticulate compositions typically including a p21 activated kinase (PAK) inhibitor and a lipid-based delivery vehicle are also provided. In preferred embodiments, the lipid-based delivery vehicle is a liposome, most preferably a sterically-stabilized liposome. Typically the lipid-based delivery vehicle includes one or more phospholipids, and optionally a sterol. In some embodiments, at least one of the phospholipids is PEGylated. In particular embodiments, the lipid-based delivery vehicle includes DSPC, DSPE-PEG2000, and cholesterol. In specific embodiments, the ratio of DSPC, DSPE-PEG, and cholesterol is 9:1:5. The nanoparticulate composition typically includes a PAK inhibitor, preferably a PAK-1 inhibitor such as IPA-3 or a derivative, prodrug, or pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
October 19, 2022
Date of Patent:
April 30, 2024
Assignee:
UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
Inventors:
Somanath Rammohan Shenoy, Brian S. Cummings, Wided Najahi-Missaoui
Abstract: The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.
Type:
Grant
Filed:
November 27, 2023
Date of Patent:
April 30, 2024
Assignee:
EXELA PHARMA SCIENCES, LLC
Inventors:
John Maloney, Aruna Koganti, Phanesh Koneru
Abstract: Polymeric transfection reagents for delivery of nucleic acids to cells, pharmaceutical compositions comprising same, and methods of preparing and using same are provided. A compound comprises polyethylenimine, a lipid selected from cholesterol, lauric acid, palmitic acid, or stearic acid, and optionally, a histidine. A nanoparticle comprises the compound complexed to a nucleic acid. A composition or pharmaceutical composition comprises the nanoparticle and a pharmaceutically acceptable carrier, anti-fouling agent, targeting ligand, or combinations thereof. A method of treating, preventing, or ameliorating a disease in a subject comprises administering to the subject an effective amount of the nanoparticle or the composition or pharmaceutical composition.
Type:
Grant
Filed:
June 18, 2018
Date of Patent:
April 23, 2024
Assignee:
RJH BIOSCIENCES INC.
Inventors:
Hasan Uludag, Remant Badahur Kc, Juliana Valencia-Serna
Abstract: A composition comprising: at least one compound of the chemical structure: [ H x ? O ( x - 1 ) 2 ] ? Z y wherein x is and odd integer ?3; y is an integer between 1 and 20; and Z is one of a monoatomic ion from Groups 14 through 17 having a charge value between ?1 and ?3 or a polyatomic ion having a charge between ?1 and ?3; or Z?—Hx?Ox?-y? wherein x? is and integer greater than 3 y? is an integer less than x?; and Z? is one of a monoatomic cation, a polyatomic ion or a cationic complex; and at least one of a humectant emollient or carrier.
Abstract: A composition comprising: at least one compound of the chemical structure: ? H x ? O ( x - 1 ) 2 ? ? Z y wherein x is an odd integer ?3; y is an integer between 1 and 20; and Z is one of a monoatomic ion from Groups 14 through 17 having a charge value between ?1 and ?3 or a polyatomic ion having a charge between ?1 and ?3; or Z?—Hx?Ox?-y? wherein x? is an integer greater than 3 y? is an integer less than x?; and Z? is one of a monoatomic cation, a polyatomic ion or a cationic complex; and at least one of a humectant emollient or carrier.
Abstract: The present disclosure discloses a method for inhibiting formation of a biofilm of bacteria. Specifically, the method may include treating the bacteria with an effective amount of a coumarin-chalcone compound. While inhibiting the formation of the biofilm of the bacteria, the effective amount of the coumarin-chalcone compound may reduce virulences of the bacteria and enhance a susceptibility of the bacteria to an antibiotic when applied in combination with the antibiotic. The present disclosure further discloses a composition including an effective amount of the coumarin-chalcone compound. The composition may be used to inhibit the formation of the biofilm of bacteria. The composition may also include an antibiotic, a minimal inhibitory concentration and a minimal biofilm eliminate concentration of which are reduced when the composition is used.
Type:
Grant
Filed:
November 12, 2021
Date of Patent:
April 9, 2024
Assignee:
INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCES
Inventors:
Luyan Ma, Qing Wei, Pramod Bhasme, Di Wang
Abstract: ABSTRACT A cosmetic composition for skin containing a solvent A, a solvent B, and a polymer C, where a boiling point of the solvent A is lower than 99° C., and a distance Ra of the Hansen solubility parameter of the solvent A to water is 36 or less; a boiling point of the solvent B is 150° C. or higher, and a distance Ra of the Hansen solubility parameter of the solvent B to water is 40 or more; and the solvent B is compatible with the solvent A, and the polymer C is soluble in the solvent A but insoluble in the solvent B. A cosmetic coating film for skin includes the cosmetic composition.
Abstract: L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates for treatment, amelioration and/or prevention of protein aggregation/tangles/plaques and diseases associated with protein aggregation/tangles/plaques. In particular, treatments and uses for L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates include Alzheimer's disease (AD), Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and Huntington disease (HD).
Type:
Grant
Filed:
March 28, 2014
Date of Patent:
March 5, 2024
Assignee:
THE INSTITUTE FOR ETHNOMEDICINE
Inventors:
Paul Alan Cox, Sandra Anne Banack, Deborah C. Mash
Abstract: Oral care compositions comprising an amino acid and stannous ion source, especially in the absence of a soluble zinc ion source, are provided for promoting Gum Health of a user.
Abstract: The present invention relates to lipid nanoparticles for in vivo drug delivery and uses thereof, and the lipid nanoparticle are liver tissue-specific, have excellent biocompatibility and can deliver a gene therapeutic agent with high efficiency, and thus it can be usefully used in related technical fields such as lipid nanoparticle mediated gene therapy.
Type:
Grant
Filed:
August 1, 2022
Date of Patent:
February 27, 2024
Assignee:
EnhancedBio Inc.
Inventors:
Hyukjin Lee, Minjeong Kim, Hansaem Jeong, Hyokyoung Kwon, Yunmi Seo, Michaela Jeong
Abstract: The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.
Type:
Grant
Filed:
May 27, 2022
Date of Patent:
February 20, 2024
Assignee:
BIOVERSYS AG
Inventors:
Glenn E. Dale, Sergio Lociuro, Marc Gitzinger, Stefano Biondi, Marilyne Bourotte
Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
Type:
Grant
Filed:
August 29, 2022
Date of Patent:
February 6, 2024
Assignee:
Karuna Therapeutics, Inc.
Inventors:
Aimesther Betancourt, Bruce Rehlaender, Roch Thibert
Abstract: The present invention relates to a dental composition comprising a photoinitiator system comprising a particulate carrier supporting a coinitiator covalently bonded to the surface of the carrier. Furthermore, the present invention relates to a use of the particulate carrier in a dental composition. The particulate carrier displays multiple covalently bonded tertiary amino groups and/or tertiary phosphine groups on the surface, for crosslinking monomers, oligomers and/or polymers having one or more polymerizable double bonds.
Type:
Grant
Filed:
October 4, 2022
Date of Patent:
January 30, 2024
Assignee:
DENTSPLY SIRONA INC.
Inventors:
Maximilian Maier, Joachim E. Klee, Christian Scheufler, Caroline Renn, Florian Szillat
Abstract: The present invention relates to a novel chemical compound for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.
Type:
Grant
Filed:
December 1, 2021
Date of Patent:
January 16, 2024
Assignee:
Tapestry Pharmaceuticals, Inc.
Inventors:
James D. McChesney, Gilles H. Tapolsky, David Lloyd Emerson, John Marshall, Michael Kurman, Manuel R. Modiano
Abstract: Described herein are methods, formulations and kits for treating a patient with triple-negative breast cancer with nanoparticle complexes comprising a carrier protein (e.g., albumin), paclitaxel and a binding agent specific for a target antigen expressed by the cells (e.g., an anti-VEGF antibody).
Type:
Grant
Filed:
January 26, 2023
Date of Patent:
January 16, 2024
Assignee:
Mayo Foundation for Medical Education and Research
Inventors:
Gerald F. Swiss, Jesse Crowne, Svetomir N. Markovic, Wendy K. Nevala